These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

664 related items for PubMed ID: 19170589

  • 41. [Renin inhibitors--new direction in the treatment of arterial hypertension].
    Vasiuk IuA, Sadulaeva IA, Iushchuk EN, Trofimenko OS, Chirkov MV, Fedoseeva VS, Kulikov KG.
    Ter Arkh; 2010; 82(9):53-9. PubMed ID: 21086622
    [Abstract] [Full Text] [Related]

  • 42. Direct inhibition of renin: a physiological approach to treat hypertension and cardiovascular disease.
    Ram CV.
    Future Cardiol; 2009 Sep; 5(5):453-65. PubMed ID: 19715410
    [Abstract] [Full Text] [Related]

  • 43. Renin inhibition: should it supplant ACE inhibitors and ARBS in high risk patients?
    Gaddam KK, Oparil S.
    Curr Opin Nephrol Hypertens; 2008 Sep; 17(5):484-90. PubMed ID: 18695389
    [Abstract] [Full Text] [Related]

  • 44. Renin inhibitors: novel agents for renoprotection or a better angiotensin receptor blocker for blood pressure lowering?
    Pimenta E, Oparil S.
    Cardiol Clin; 2008 Nov; 26(4):527-35. PubMed ID: 18929229
    [Abstract] [Full Text] [Related]

  • 45. Aliskiren: the first direct renin inhibitor available for clinical use.
    Morganti A, Lonati C.
    J Nephrol; 2011 Nov; 24(5):541-9. PubMed ID: 21786226
    [Abstract] [Full Text] [Related]

  • 46. Is there a future for direct renin inhibitors?
    Chaudhary K, Nistala R, Whaley-Connell A.
    Expert Opin Investig Drugs; 2010 May; 19(5):653-61. PubMed ID: 20380486
    [Abstract] [Full Text] [Related]

  • 47. Pharmacokinetics, safety, and tolerability of the oral Renin inhibitor aliskiren in patients with hepatic impairment.
    Vaidyanathan S, Warren V, Yeh C, Bizot MN, Dieterich HA, Dole WP.
    J Clin Pharmacol; 2007 Feb; 47(2):192-200. PubMed ID: 17244770
    [Abstract] [Full Text] [Related]

  • 48. Clinical pharmacokinetics and pharmacodynamics of aliskiren.
    Vaidyanathan S, Jarugula V, Dieterich HA, Howard D, Dole WP.
    Clin Pharmacokinet; 2008 Feb; 47(8):515-31. PubMed ID: 18611061
    [Abstract] [Full Text] [Related]

  • 49. Direct renin inhibition with aliskiren in hypertension and target organ damage.
    Müller DN, Luft FC.
    Clin J Am Soc Nephrol; 2006 Mar; 1(2):221-8. PubMed ID: 17699210
    [Abstract] [Full Text] [Related]

  • 50. Renin inhibition with aliskiren.
    Wuerzner G, Azizi M.
    Clin Exp Pharmacol Physiol; 2008 Apr; 35(4):426-30. PubMed ID: 18307734
    [Abstract] [Full Text] [Related]

  • 51. Renal and hormonal responses to direct renin inhibition with aliskiren in healthy humans.
    Fisher ND, Jan Danser AH, Nussberger J, Dole WP, Hollenberg NK.
    Circulation; 2008 Jun 24; 117(25):3199-205. PubMed ID: 18559696
    [Abstract] [Full Text] [Related]

  • 52.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 53. A comparison of the tolerability of the direct renin inhibitor aliskiren and lisinopril in patients with severe hypertension.
    Strasser RH, Puig JG, Farsang C, Croket M, Li J, van Ingen H.
    J Hum Hypertens; 2007 Oct 24; 21(10):780-7. PubMed ID: 17541390
    [Abstract] [Full Text] [Related]

  • 54. Renin-angiotensin-aldosterone system blockade in high-risk hypertensive patients: current approaches and future trends.
    Gullapalli N, Bloch MJ, Basile J.
    Ther Adv Cardiovasc Dis; 2010 Dec 24; 4(6):359-73. PubMed ID: 20965951
    [Abstract] [Full Text] [Related]

  • 55. Efficacy, safety and tolerability of aliskiren, a direct renin inhibitor, in women with hypertension: a pooled analysis of eight studies.
    Gradman AH, Weir MR, Wright M, Bush CA, Keefe DL.
    J Hum Hypertens; 2010 Nov 24; 24(11):721-9. PubMed ID: 20200550
    [Abstract] [Full Text] [Related]

  • 56. Renin inhibition with aliskiren: where are we now, and where are we going?
    Azizi M, Webb R, Nussberger J, Hollenberg NK.
    J Hypertens; 2006 Feb 24; 24(2):243-56. PubMed ID: 16508564
    [Abstract] [Full Text] [Related]

  • 57.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 58. Safety and efficacy of aliskiren in the treatment of hypertension: a systematic overview.
    Angeli F, Reboldi G, Mazzotta G, Poltronieri C, Verdecchia P.
    Expert Opin Drug Saf; 2012 Jul 24; 11(4):659-70. PubMed ID: 22724663
    [Abstract] [Full Text] [Related]

  • 59. Pharmacokinetics and pharmacodynamics of aliskiren, an oral direct renin inhibitor.
    Buczko W, Hermanowicz JM.
    Pharmacol Rep; 2008 Jul 24; 60(5):623-31. PubMed ID: 19066408
    [Abstract] [Full Text] [Related]

  • 60. [Renin as a target of direct pharmacological block in arterial hypertension].
    Mukhin NA, Fomin VV.
    Ter Arkh; 2009 Jul 24; 81(8):5-9. PubMed ID: 19799192
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 34.